Your browser doesn't support javascript.
loading
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard, Gerhardt; Murphy, Laura; Clarke, Noel W; Cross, William; Jones, Robert J; Parker, Christopher C; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Amos, Claire L; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Chowdhury, Simon; Malik, Zafar; Russell, J Martin; Gilson, Clare; Rush, Hannah; Bowen, Jo; Lydon, Anna; Pedley, Ian; O'Sullivan, Joe M; Birtle, Alison; Gale, Joanna; Srihari, Narayanan; Thomas, Carys; Tanguay, Jacob; Wagstaff, John; Das, Prantik; Gray, Emma; Alzoueb, Mymoona; Parikh, Omi; Robinson, Angus; Syndikus, Isabel; Wylie, James; Zarkar, Anjali; Thalmann, George; de Bono, Johann S; Dearnaley, David P; Mason, Malcolm D; Gilbert, Duncan; Langley, Ruth E; Millman, Robin; Matheson, David; Sydes, Matthew R; Brown, Louise C; Parmar, Mahesh K B; James, Nicholas D.
Afiliação
  • Attard G; Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk.
  • Murphy L; MRC Clinical Trials Unit at University College London, London, UK.
  • Clarke NW; The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Cross W; St James's University Hospital, Leeds, UK.
  • Jones RJ; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Parker CC; Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Gillessen S; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Universita della Svizzera Italiana, Lugano, Switzerland.
  • Cook A; MRC Clinical Trials Unit at University College London, London, UK.
  • Brawley C; MRC Clinical Trials Unit at University College London, London, UK.
  • Amos CL; MRC Clinical Trials Unit at University College London, London, UK.
  • Atako N; MRC Clinical Trials Unit at University College London, London, UK.
  • Pugh C; MRC Clinical Trials Unit at University College London, London, UK.
  • Buckner M; MRC Clinical Trials Unit at University College London, London, UK.
  • Chowdhury S; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Malik Z; Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
  • Russell JM; University of Glasgow Institute of Cancer Sciences, Glasgow, UK.
  • Gilson C; MRC Clinical Trials Unit at University College London, London, UK.
  • Rush H; MRC Clinical Trials Unit at University College London, London, UK.
  • Bowen J; Cheltenham General Hospital, Cheltenham, UK.
  • Lydon A; Torbay and South Devon NHS Foundation Trust, Torbay, UK.
  • Pedley I; Northern Centre for Cancer Care, Newcastle upon Tyne, UK.
  • O'Sullivan JM; Queen's University Belfast, Belfast, UK.
  • Birtle A; Royal Preston Hospital, Preston, UK.
  • Gale J; Queen Alexandra Hospital, Portsmouth, UK.
  • Srihari N; Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
  • Thomas C; Kent Oncology Centre, Maidstone, UK.
  • Tanguay J; Velindre Hospital, Cardiff, UK.
  • Wagstaff J; Singleton Hospital, Swansea, UK.
  • Das P; Royal Derby Hospital, Derby, UK.
  • Gray E; Yeovil District Hospital NHS Foundation Trust, Yeovil, UK; Musgrove Park Hospital, Taunton, UK.
  • Alzoueb M; Weston Park Hospital, Sheffield, UK.
  • Parikh O; Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
  • Robinson A; Royal Sussex County Hospital, Brighton, UK.
  • Syndikus I; Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
  • Wylie J; The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Zarkar A; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Thalmann G; Inselspital Universitatsspital Bern, Bern, Switzerland.
  • de Bono JS; Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Dearnaley DP; Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Mason MD; Cardiff University, Cardiff, UK.
  • Gilbert D; MRC Clinical Trials Unit at University College London, London, UK.
  • Langley RE; MRC Clinical Trials Unit at University College London, London, UK.
  • Millman R; MRC Clinical Trials Unit at University College London, London, UK.
  • Matheson D; Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK.
  • Sydes MR; MRC Clinical Trials Unit at University College London, London, UK.
  • Brown LC; MRC Clinical Trials Unit at University College London, London, UK.
  • Parmar MKB; MRC Clinical Trials Unit at University College London, London, UK.
  • James ND; Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
Lancet ; 399(10323): 447-460, 2022 01 29.
Article em En | MEDLINE | ID: mdl-34953525
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Prednisolona / Protocolos de Quimioterapia Combinada Antineoplásica / Acetato de Abiraterona / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies / Systematic_reviews Limite: Humans / Male Idioma: En Revista: Lancet Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Prednisolona / Protocolos de Quimioterapia Combinada Antineoplásica / Acetato de Abiraterona / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies / Systematic_reviews Limite: Humans / Male Idioma: En Revista: Lancet Ano de publicação: 2022 Tipo de documento: Article